Co-therapy with S-adenosylmethionine and nicotinamide riboside improves t-cell survival and function in Arts Syndrome (PRPS1 deficiency)

Nina Lenherr; John Christodoulou; John Duley; Doreen Dobritzsch; Lynette Fairbanks; Alexandre N. Datta; Isabel Filges; Nicolas Gürtler; Jeroen Roelofsen; André B. P. van Kuilenburg; Claudia Kemper; Erin E. West; Gabor Szinnai; Martina Huemer

doi:10.1016/j.ymgmr.2021.100709

Co-therapy with S-adenosylmethionine and nicotinamide riboside improves t-cell survival and function in Arts Syndrome (PRPS1 deficiency)

Nina Lenherr
, John Christodoulou
, John Duley
, Doreen Dobritzsch
, Lynette Fairbanks
, Alexandre N. Datta
, Isabel Filges
, Nicolas Gürtler
, Jeroen Roelofsen
, André B. P. van Kuilenburg
, Claudia Kemper
, Erin E. West
, Gabor Szinnai
, Martina Huemer^*

^*Corresponding author for this work

University of Basel
University of Melbourne
University of Queensland
Uppsala University
Paediatric Allergy Group, Department of Women and Children's Health, King's College London, St. Thomas' Hospital, London, UK
University of Amsterdam
National Institutes of Health
University of Zurich

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Arts syndrome or phosphoribosyl-pyrophosphate-synthetase-1 (PRPS1) deficiency is caused by loss-of-function mutations in the PRPS1 gene (Xq22.3). PRPS1 is an initial and essential step for the synthesis of the nucleotides of purines, pyrimidines, and nicotinamide. Classically, affected males present with sensorineural hearing loss, optic atrophy, muscular hypotonia, developmental impairment, and recurrent severe respiratory infections early in life. Treatment of a 3-year old boy with S-adenosylmethionine (SAM) replenished erythrocyte purine nucleotides of adenosine and guanosine, while SAM and nicotinamide riboside co-therapy further improved his clinical phenotype as well as T-cell survival and function.

Original language	English
Article number	100709
Journal	Molecular genetics and metabolism reports
Volume	26
DOIs	https://doi.org/10.1016/j.ymgmr.2021.100709
Publication status	Published - 1 Mar 2021

Access to Document

10.1016/j.ymgmr.2021.100709

Cite this

Lenherr, N., Christodoulou, J., Duley, J., Dobritzsch, D., Fairbanks, L., Datta, A. N., Filges, I., Gürtler, N., Roelofsen, J., van Kuilenburg, A. B. P., Kemper, C., West, E. E., Szinnai, G., & Huemer, M. (2021). Co-therapy with S-adenosylmethionine and nicotinamide riboside improves t-cell survival and function in Arts Syndrome (PRPS1 deficiency). Molecular genetics and metabolism reports, 26, Article 100709. https://doi.org/10.1016/j.ymgmr.2021.100709

@article{77b6eeec89fa4cf895989b1667e5ec25,

title = "Co-therapy with S-adenosylmethionine and nicotinamide riboside improves t-cell survival and function in Arts Syndrome (PRPS1 deficiency)",

abstract = "Arts syndrome or phosphoribosyl-pyrophosphate-synthetase-1 (PRPS1) deficiency is caused by loss-of-function mutations in the PRPS1 gene (Xq22.3). PRPS1 is an initial and essential step for the synthesis of the nucleotides of purines, pyrimidines, and nicotinamide. Classically, affected males present with sensorineural hearing loss, optic atrophy, muscular hypotonia, developmental impairment, and recurrent severe respiratory infections early in life. Treatment of a 3-year old boy with S-adenosylmethionine (SAM) replenished erythrocyte purine nucleotides of adenosine and guanosine, while SAM and nicotinamide riboside co-therapy further improved his clinical phenotype as well as T-cell survival and function.",

author = "Nina Lenherr and John Christodoulou and John Duley and Doreen Dobritzsch and Lynette Fairbanks and Datta, \{Alexandre N.\} and Isabel Filges and Nicolas G{\"u}rtler and Jeroen Roelofsen and \{van Kuilenburg\}, \{Andr{\'e} B. P.\} and Claudia Kemper and West, \{Erin E.\} and Gabor Szinnai and Martina Huemer",

note = "Funding Information: We thank our patient and his parents for their cooperation and support. We are grateful for clinical support from our colleagues Sarabel Frey, Anja Palmowski-Wolfe, Benno R{\"o}thlisberger, Daniel Trachsel and Andreas W{\"o}rner and we thank Gunhild Unterstab and Christoph Hess for their help with sample preparation. The research conducted at the Murdoch Children's Research Institute was supported by the Victorian Government's Operational Infrastructure Support Program . Publisher Copyright: {\textcopyright} 2021 The Authors",

year = "2021",

month = mar,

day = "1",

doi = "10.1016/j.ymgmr.2021.100709",

language = "English",

volume = "26",

journal = "Molecular genetics and metabolism reports",

issn = "2214-4269",

publisher = "Elsevier BV",

}

Lenherr, N, Christodoulou, J, Duley, J, Dobritzsch, D, Fairbanks, L, Datta, AN, Filges, I, Gürtler, N, Roelofsen, J, van Kuilenburg, ABP, Kemper, C, West, EE, Szinnai, G & Huemer, M 2021, 'Co-therapy with S-adenosylmethionine and nicotinamide riboside improves t-cell survival and function in Arts Syndrome (PRPS1 deficiency)', Molecular genetics and metabolism reports, vol. 26, 100709. https://doi.org/10.1016/j.ymgmr.2021.100709

TY - JOUR

T1 - Co-therapy with S-adenosylmethionine and nicotinamide riboside improves t-cell survival and function in Arts Syndrome (PRPS1 deficiency)

AU - Lenherr, Nina

AU - Christodoulou, John

AU - Duley, John

AU - Dobritzsch, Doreen

AU - Fairbanks, Lynette

AU - Datta, Alexandre N.

AU - Filges, Isabel

AU - Gürtler, Nicolas

AU - Roelofsen, Jeroen

AU - van Kuilenburg, André B. P.

AU - Kemper, Claudia

AU - West, Erin E.

AU - Szinnai, Gabor

AU - Huemer, Martina

N1 - Funding Information: We thank our patient and his parents for their cooperation and support. We are grateful for clinical support from our colleagues Sarabel Frey, Anja Palmowski-Wolfe, Benno Röthlisberger, Daniel Trachsel and Andreas Wörner and we thank Gunhild Unterstab and Christoph Hess for their help with sample preparation. The research conducted at the Murdoch Children's Research Institute was supported by the Victorian Government's Operational Infrastructure Support Program . Publisher Copyright: © 2021 The Authors

PY - 2021/3/1

Y1 - 2021/3/1

N2 - Arts syndrome or phosphoribosyl-pyrophosphate-synthetase-1 (PRPS1) deficiency is caused by loss-of-function mutations in the PRPS1 gene (Xq22.3). PRPS1 is an initial and essential step for the synthesis of the nucleotides of purines, pyrimidines, and nicotinamide. Classically, affected males present with sensorineural hearing loss, optic atrophy, muscular hypotonia, developmental impairment, and recurrent severe respiratory infections early in life. Treatment of a 3-year old boy with S-adenosylmethionine (SAM) replenished erythrocyte purine nucleotides of adenosine and guanosine, while SAM and nicotinamide riboside co-therapy further improved his clinical phenotype as well as T-cell survival and function.

AB - Arts syndrome or phosphoribosyl-pyrophosphate-synthetase-1 (PRPS1) deficiency is caused by loss-of-function mutations in the PRPS1 gene (Xq22.3). PRPS1 is an initial and essential step for the synthesis of the nucleotides of purines, pyrimidines, and nicotinamide. Classically, affected males present with sensorineural hearing loss, optic atrophy, muscular hypotonia, developmental impairment, and recurrent severe respiratory infections early in life. Treatment of a 3-year old boy with S-adenosylmethionine (SAM) replenished erythrocyte purine nucleotides of adenosine and guanosine, while SAM and nicotinamide riboside co-therapy further improved his clinical phenotype as well as T-cell survival and function.

UR - https://www.scopus.com/pages/publications/85099614850

U2 - 10.1016/j.ymgmr.2021.100709

DO - 10.1016/j.ymgmr.2021.100709

M3 - Article

C2 - 33532242

SN - 2214-4269

VL - 26

JO - Molecular genetics and metabolism reports

JF - Molecular genetics and metabolism reports

M1 - 100709

ER -

Co-therapy with S-adenosylmethionine and nicotinamide riboside improves t-cell survival and function in Arts Syndrome (PRPS1 deficiency)

Abstract

Access to Document

Other files and links

Fingerprint

Cite this